The Black Soldier Fly Hermetia illucens Larva Presents an Antimicrobial Activity in Response to Clostridioides difficile Exposure.

阅读:3
作者:Melchior Aviel, Azrad Maya, Fichtman Boris, Peretz Avi
Clostridioides difficile C. difficile infection (CDI) is the primary cause of antibiotic-associated diarrhea and is highly resistant to antibiotics. The black soldier fly Hermetia illucens (BSF) has a large antimicrobial peptide (AMP) repertoire effective against various infectious diseases. This study evaluated the activity of BSF hemolymph-extracted AMPs, with particular focus on defensin-like peptide 4 (DLP4), against C. difficile isolates. In the current study, BSF larvae (BSFL) were injected with or fed pathogenic C. difficile strain 630. The effects of post-infection hemolymph and of synthetic AMPs on 18 clinical antibiotic-resistant C. difficile isolates were assessed using the disk diffusion test. Real-time RT PCR was conducted to measure expression of five hemolymph AMP genes in infected larvae. Bacterial counts were measured after DLP4 exposure and cytotoxicity of DLP4 against Caco-2 epithelial cells was tested using the XTT method. Bacterial outer layer damage was evaluated by scanning electron microscopy. Hemolymph extracted from C. difficile-infected BSFL had a significant inhibitory effect on C. difficile growth. All five AMPs were upregulated following exposure to pathogenic C. difficile. DLP4 was the most potent AMP, with MICs in the range of 64-250 µg/ml for the different clinical isolates. DLP4 exhibited rapid-onset bactericidal activity (1 hour), by inducing holes in the bacterial outer layer, while having no cytotoxic effect on human epithelial cells. In conclusion, BSF hemolymph-derived DLP4 bears antimicrobial properties against antibiotic-resistant C. difficile isolates. DLP4 may represent a promising and novel approach for the treatment of C. difficile infections.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。